Download MendeleyNovel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1.
Ryu, S., Park, J.E., Ham, Y.J., Lim, D.C., Kwiatkowski, N.P., Kim, D.H., Bhunia, D., Kim, N.D., Yaffe, M.B., Son, W., Kim, N., Choi, T.I., Swain, P., Kim, C.H., Lee, J.Y., Gray, N.S., Lee, K.S., Sim, T.(2022) J Med Chem 65: 1915-1932
- PubMed: 35029981
- DOI: https://doi.org/10.1021/acs.jmedchem.1c01359
- Primary Citation of Related Structures:
7MSO - PubMed Abstract:
The polo-box domain (PBD) of Plk1 is a promising target for cancer therapeutics. We designed and synthesized novel phosphorylated macrocyclic peptidomimetics targeting PBD based on acyclic phosphopeptide PMQSpTPL. The inhibitory activities of 16e on Plk1-PBD is >30-fold higher than those of PMQSpTPL. Both 16a and 16e possess excellent selectivity for Plk1-PBD over Plk2/3-PBD. Analysis of the cocrystal structure of Plk1-PBD in complex with 16a reveals that the 3-(trifluoromethyl)benzoyl group in 16a interacts with Arg516 through a π-stacking interaction. This π-stacking interaction, which has not been reported previously, provides insight into the design of novel and potent Plk1-PBD inhibitors. Furthermore, 16h , a PEGlyated macrocyclic phosphopeptide derivative, induces Plk1 delocalization and mitotic failure in HeLa cells. Also, the number of phospho-H3-positive cells in a zebrafish embryo increases in proportion to the amount of 16a . Collectively, the novel macrocyclic peptidomimetics should serve as valuable templates for the design of potent and novel Plk1-PBD inhibitors.
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.
Organizational Affiliation:
